In summary, we demonstrated the incorporation of synthetic MCP-1 peptide within a PAM delivery system enhanced the protein mimetic properties of the peptide, and applied it towards improved anticancer efficacy using prostate cancer cells in vitro. Future studies will assess whether MCP-1 PAMs can competitively inhibit the interaction of native MCP-1 protein with CCR2, which is known to elicit cancer progression and metastasis. Given the importance of chemokines and its receptors in the effects of cancer pathogenesis, our findings show therapeutic potential of combining synthetic peptides into micelles to mimic the ability of the protein in the treatment of various diseases.
展开▼
